✦ LIBER ✦

Binding of a new multidrug resistance modulator, S9788, to human plasma proteins and erythrocytes

✍ Scribed by Saïk Urien; Phuc Nguyen; Gérard Bastian; Catherine Lucas; Jean-Paul Tillement

Book ID: 110591279
Publisher: Springer US
Year: 1995
Tongue: English
Weight: 356 KB
Volume: 13
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf02614218

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Binding of Pyrimethamine to Human Plasma

Binding of Pyrimethamine to Human Plasma Proteins and Erythrocytes

✍ Anita C. Rudy; Wesley J. Poynor 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 1003 KB

Influence of S9788, a new modulator of m

Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in p-glycoprotein-expressing MCF7 human breast adenocarcinoma cells

✍ Jean-Louis Merlin; Sophie Marchal; Carole Ramacci; Alain Dieterlen; Guy Schultz; 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 903 KB

Binding of a new vinca alkaloid derivati

Binding of a new vinca alkaloid derivative, S12363, to human plasma proteins and platelets. Usefulness of an erythrocyte partitioning technique

✍ Saïk Urien; Gérard Bastian; Catherine Lucas; Jean-Pierre Bizzari; Jean-Paul Till 📂 Article 📅 1992 🏛 Springer US 🌐 English ⚖ 415 KB

Phase I clinical and pharmacokinetic stu

Phase I clinical and pharmacokinetic study of S9788, a new multidrug-resistance reversal agent given alone and in combination with doxorubicin to patients with advanced solid tumors

✍ Brigitte Tranchand; Gilles Catimel; Catherine Lucas; Marlis Sarkany; Gérard Bast 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 222 KB

Method for the analysis of S9788, a drug

Method for the analysis of S9788, a drug to reverse resistance to anticancer agents, in animal plasma and human plasma and serum by high-performance liquid chromatography with ultraviolet detection

✍ D.M. Bakes; N.D. Turner; B.H. Gordon; M.P. Hiley; B. Walther; C. Lucas 📂 Article 📅 1993 🏛 Elsevier Science ⚖ 780 KB

BINDING CHARACTERISTICS OF KNI-272 TO PL

BINDING CHARACTERISTICS OF KNI-272 TO PLASMA PROTEINS, A NEW POTENT TRIPEPTIDE HIV PROTEASE INHIBITOR

✍ A. Kiriyama; T. Nishiura; M. Ishino; Y. Yamamoto; I. Ogita; Y. Kiso; K. Takada 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 690 KB

The binding characteristics of KNI-272, a potent and selective human immunodeficiency virus (HIV) protease inhibitor, were evaluated in rat and human plasma, and in solutions of human a,-acid glycoprotein (AAG) and human serum albumin (HSA). The unbound fractions (F,) of KNI-272 were 12.13 and 2.24%